Effects of labetalol and propranolol on blood pressure at rest and during isometric and dynamic exercise

Effects of labetalol and propranolol on the peripheral circulation in hypertensive patients

Eleven patients with essential hypertension participated in a double-blind cross-over comparison of labetalol (L) and propranolol (P). Each drug was given for 5--8 weeks. The dose reducing the supine diastolic blood pressure when given b.d. to or below 90 mm Hg was titrated out. At the end of each period, isometric exercise (sustained handgrip) and calf plethysmography were performed. L (mean daily dose 636 mg) was slightly more effective in lowering supine and standing blood pressure than P (mean dose 276 mg). There was no significant difference between the drugs in their effect on the blood-pressure response to handgrip. However, compared with no treatment, L attenuated the blood-pressure rise at near-maximal handgrip; this has not been reported with other beta-blockers. Resting vascular resistance and basal vascular tone were significantly lower (20%, p less than 0.05) during treatment with labetalol than when the patients were taking propranolol. - The differences may be explained by the alpha-receptorblocking action of labetalol.

Haemodynamic, anti-anginal and anti-ischaemic effects of sublingual nitroglycerin: dose-response, duration and time of onset of action

To establish the time of onset of action and magnitude of response to the quickest disintegrating sublingual nitroglycerin tablet available in Scandinavia (Nitromex), nine patients with stable exercise-induced angina were studied whilst performing bicycle exercise tests. In the first session, placebo, 0.25, 0.50 and 0.75 mg sublingual nitroglycerin (Nitromex) was given in a double-blind cross-over fashion on different days. In the second session (1 h after Session 1), nitroglycerin 0.5 mg (Nitromex), placebo and 0.5 mg of a different brand of nitroglycerin were compared for the time of onset of attenuation of ST-segment depression when administered during exercise. In Session 1, there was a dose-dependent fall in systolic blood pressure and a concordant rise in heart rate whilst sitting at rest prior to exercise. Exercise time and ST-segment depression were dose-dependently prolonged, significantly by the two higher doses, (mean 20 and 26%, respectively) which did not differ from one another. In Session 2, nitroglycerin (Nitromex) caused ST-segment reversal after a mean of 123 s after administration, which was shorter than after ordinary nitroglycerin (mean 157 s) and placebo (two tests, 186 and 192 s). It is suggested that when nitroglycerin is administered during exercise, chest pain and ischaemic ECG-changes are largely improved through coronary vasodilatation and reduced afterload rather than through increased venous pooling and reduction in preload.

Pharmacology of combined alpha-beta-blockade. I

Several compounds of the chemical class arylethanolamines have been shown to possess combined alpha- or vasodilator and beta-adrenoceptor blocking properties. The first drug was labetalol (AH5158)[5-(1-hydroxy-2)1-methyl-3-phenylpropyl(amino)-ethyl (salicylamide)]. Others include medroxalol, bucindolol and YM-09538, which differ from labetalol either by the nature of the substitution on the primary benzene ring and/or on the terminal nitrogen. All of these drugs are non-selective beta-blockers, except for bucindolol whose selectivity has not been carefully defined. The rationale for the development of this group of drugs was the knowledge that blockade of one adrenoceptor subtype causes reflex stimulation of the other, i.e. vasoconstriction after nonspecific beta-blockade and tachycardia after alpha-blockade. Since both of these compensatory responses act to prevent a fall in blood pressure, a relatively weak blockade of both receptor types should act synergistically to produce a lowering of blood pressure with minimal physiological disturbance. Haemodynamic studies have confirmed that the additional alpha-blocking properties of labetalol produce a pattern of haemodynamic changes unlike that of propranolol and other simple beta-adrenoceptor blocking agents. Peripheral vascular resistance, which falls acutely during the initial administration of the drug, tends to fall further during prolonged administration and the pulse rate tends to remain only slightly lower than pretreatment levels. In addition, at normal dose levels cardiac output is maintained by a compensatory increase in stroke volume. Thus, blood pressure is lowered largely by a reduction in vascular resistance, and although the heart rate falls significantly during exercise, the cardiac output is maintained by an increase in stroke volume. This pattern of events is different to that seen with beta-blocking agents which consistently reduce cardiac output during exercise. Currently labetalol is the only member of this group of drugs which is in established clinical use. Its antihypertensive efficacy has been confirmed in many studies and it has been shown to be effective in the management of both hypertensive emergencies and in the long term management of severe hypertension. It is particularly valuable in allowing a reduction in the number of drugs required for adequate blood pressure control. The early theoretical prediction that postural hypotension would occur with high doses is now acknowledged to be labetalol's major dose-limiting side effect. Most of the available pharmacokinetic data on labetalol were derived from studies which utilised a fluorimetric assay.(ABSTRACT TRUNCATED AT 400 WORDS)

Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects

Labetalol is a combined alpha- and beta-adrenoceptor blocking agent for oral and intravenous use in the treatment of hypertension. It is a nonselective antagonist at beta-adrenoceptors and a competitive antagonist of postsynaptic alpha 1-adrenoceptors. Labetalol is more potent at beta that at alpha 1 adrenoceptors in man; the ratio of beta-alpha antagonism is 3:1 after oral and 6.9:1 after intravenous administration. Labetalol is readily absorbed in man after oral administration, but the drug, which is lipid soluble, undergoes considerable hepatic first-pass metabolism and has an absolute bioavailability of approximately 25%. There are no active metabolites, and the elimination half-life of the drug is approximately 6 hours. Unlike conventional beta-adrenoceptor blocking drugs without intrinsic sympathomimetic activity, labetalol, when given acutely, produces a decrease in peripheral vascular resistance and blood pressure with little alteration in heart rate or cardiac output. However, like conventional beta-blockers, labetalol may influence the renin-angiotensin-aldosterone system and respiratory function. Clinical studies have shown that the antihypertensive efficacy of labetalol is superior to placebo and to diuretic therapy and is at least comparable to that of conventional beta-blockers, methyldopa, clonidine and various adrenergic neuronal blockers. Labetalol administered alone or with a diuretic is often effective when other antihypertensive regimens have failed. Studies have shown that labetalol is effective in the treatment of essential hypertension, renal hypertension, pheochromocytoma, pregnancy hypertension and hypertensive emergencies. In addition, preliminary studies indicate that labetalol may be of value in the management of ischemic heart disease. The most troublesome side effect of labetalol therapy is posture-related dizziness. Other reported side effects of the drug include gastrointestinal disturbances, tiredness, headache, scalp tingling, skin rashes, urinary retention and impotence. Side effects related to the beta-adrenoceptor blocking effect of labetalol, including asthma, heart failure and Raynaud's phenomenon, have been reported in rare instances.